BioCryst Pharmaceuticals (BCRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Rare Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 34/100 (MEDIUM), 22.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 12.45% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?
- BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
- Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?
- Biopharma Stock With Layers of Technical Support in Place
- BioCryst Eyes $1B Rare-Disease Future Through External Innovation
- BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story
- BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
- BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for BioCryst Pharmaceuticals.
Full BCRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.